Cell-specific and multifunctional drug formulations for in vivo delivery
用于体内递送的细胞特异性和多功能药物制剂
基本信息
- 批准号:9483331
- 负责人:
- 金额:$ 38.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-01 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAnimal ModelAnimalsAntibodiesAntineoplastic AgentsApoptosisBindingBiomedical EngineeringBlood - brain barrier anatomyBrainBrain NeoplasmsBreast Cancer CellCellsChlorotoxinCommunicable DiseasesCytotoxic agentDetectionDiseaseDrug Delivery SystemsDrug FormulationsEngineered GeneEpithelial CellsExcisionFormulationGelatinase AGene SilencingGenetic DiseasesGoalsGuide RNAHemophilia AHepatitis BHumanImageKnowledgeLigandsLungMalignant NeoplasmsMediatingMessenger RNAMetastatic breast cancerMolecular ProbesPeptidesPharmaceutical ChemistryPharmaceutical PreparationsPharmacy (field)ProteinsResearchRespiratory syncytial virusSmall Interfering RNAStructureSystemTranslatingTreatment EfficacyViral GenomeVirusVirus Diseasescancer therapycell typecyaninedesignimage guidedimaging probein vivoinnovationinventionmedical specialtiesnanoparticleneoplastic cellnovel therapeuticsnucleolinoverexpressionprogramsreceptorsmall moleculetooltumortumor specificityuptake
项目摘要
PROJECT SUMMARY
The objectives of this project are 1) to develop cell-specific drug delivery systems; 2) to construct
multifunctional drug delivery systems; and 3) to demonstrate therapeutic efficacy of these systems in animal
models for treating genetic disorders, infectious diseases, as well as cancers. Cell-specific delivery in vivo is
one of the most challenging issues in the field of drug delivery. To address this issue, we propose two
strategies: (1) to mimic the receptor-mediated virus entry. The simple structure and composition of viruses
make them capable of specifically infecting many cell types in humans. Our research program will apply
knowledge of viral infections in order to guide the design of cell-specific delivery systems. For example,
nucleolin has been identified as a cellular receptor on epithelial cells for human respiratory syncytial virus
(RSV) in the lungs. We will utilize anti-nucleolin antibody or nucleolin ligands in order to target lung epithelial
cells. (2) to target tumor over-expressed receptors. Previous studies, however, have identified a number of
tumor over-expressed receptors, of which many are relatively unexplored and our understanding of them is
very limited. For example, Chlorotoxin, a short peptide, is capable of crossing the blood brain barrier (BBB) and
binding specifically to the matrix metalloproteinase-2 (MMP-2), which is over-expressed in brain tumor cells.
We propose to utilize these ligands in order to specifically target tumor cells. We will evaluate their tumor
specificity with imaging probes. In order to develop multifunctional drug delivery systems, we will integrate the
ligands identified from the above studies with different delivery systems such as nanoparticles and conjugates.
The payloads can be mRNA, siRNA, and small-molecule drugs to yield multifunctional delivery systems. The
delivery systems are capable of utilizing mRNA for expressing functional proteins, siRNA for gene silencing,
and small-molecule drugs for cancer therapy. By delivering mRNA encoding Cas9 and specific guide RNA
(sgRNA), we anticipate achieving gene engineering in vivo in order to find a cure for genetic disorders such as
hemophilia and to deplete viral genome for treating viral infections such as hepatitis B. In addition, we have
designed Chlorotoxin-Cyanine-Drug (CCD) as a multifunctional conjugate in order to specifically deliver near-
infrared molecular probes and cytotoxic agents to brain metastatic breast cancer (BMBC) tumor cells. After
administration, CCD conjugates will cross the BBB and bind with MMP-2 on BMBC cells, triggering the cellular
uptake of the CCD. Cyanine probes will facilitate imaging-guided tumor resection. Meanwhile, cytotoxic agents
will induce the apoptosis of tumor cells, which are below detection limits of imaging and for which surgical
removal is not a possibility. Our research goal is to translate the innovation of this research strategy in order to
develop better drug delivery tools to treat diverse diseases.
项目概要
该项目的目标是1)开发细胞特异性药物输送系统; 2)构建
多功能药物输送系统; 3) 证明这些系统在动物身上的治疗效果
治疗遗传性疾病、传染病和癌症的模型。体内细胞特异性递送是
药物输送领域最具挑战性的问题之一。为了解决这个问题,我们提出两个建议
策略:(1)模仿受体介导的病毒进入。病毒的简单结构和组成
使它们能够特异性感染人类的多种细胞类型。我们的研究计划将适用
病毒感染的知识,以指导细胞特异性递送系统的设计。例如,
核仁素已被鉴定为人呼吸道合胞病毒上皮细胞上的细胞受体
(RSV) 在肺部。我们将利用抗核仁素抗体或核仁素配体来靶向肺上皮细胞
细胞。 (2)针对肿瘤过度表达的受体。然而,之前的研究已经确定了一些
肿瘤过度表达的受体,其中许多受体相对尚未被探索,我们对它们的理解是
非常有限。例如,氯毒素(Chlorotoxin)是一种短肽,能够穿过血脑屏障(BBB)并
特异性结合基质金属蛋白酶-2 (MMP-2),该酶在脑肿瘤细胞中过度表达。
我们建议利用这些配体来特异性靶向肿瘤细胞。我们将评估他们的肿瘤
成像探针的特异性。为了开发多功能药物输送系统,我们将整合
从上述研究中鉴定出的配体具有不同的递送系统,例如纳米颗粒和缀合物。
有效负载可以是 mRNA、siRNA 和小分子药物,以产生多功能递送系统。这
递送系统能够利用 mRNA 表达功能性蛋白质,利用 siRNA 进行基因沉默,
以及用于癌症治疗的小分子药物。通过传递编码Cas9的mRNA和特定的向导RNA
(sgRNA),我们期望在体内实现基因工程,以便找到治疗遗传性疾病的方法,例如
血友病并消除病毒基因组以治疗乙型肝炎等病毒感染。此外,我们还有
设计了氯毒素-花青-药物(CCD)作为多功能缀合物,以特异性地传递近-
针对脑转移性乳腺癌 (BMBC) 肿瘤细胞的红外分子探针和细胞毒剂。后
给药后,CCD缀合物将穿过BBB并与BMBC细胞上的MMP-2结合,触发细胞
CCD 的吸收。花青探针将有助于成像引导的肿瘤切除。同时,细胞毒剂
会诱导肿瘤细胞凋亡,这些细胞凋亡低于成像检测限,需要手术治疗
移除是不可能的。我们的研究目标是将这一研究策略的创新转化为
开发更好的药物输送工具来治疗多种疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yizhou Dong其他文献
Yizhou Dong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yizhou Dong', 18)}}的其他基金
Construction of in vivo mRNA delivery systems
体内 mRNA 递送系统的构建
- 批准号:
10553241 - 财政年份:2022
- 资助金额:
$ 38.5万 - 项目类别:
Construction of in vivo mRNA delivery systems
体内 mRNA 递送系统的构建
- 批准号:
10330667 - 财政年份:2022
- 资助金额:
$ 38.5万 - 项目类别:
Integration of adjuvant derived nanoparticles and engineered mRNA for HIV vaccine discovery
佐剂衍生纳米粒子与工程 mRNA 的整合用于 HIV 疫苗的发现
- 批准号:
10618542 - 财政年份:2022
- 资助金额:
$ 38.5万 - 项目类别:
Construction of in vivo mRNA delivery systems
体内 mRNA 递送系统的构建
- 批准号:
10731953 - 财政年份:2022
- 资助金额:
$ 38.5万 - 项目类别:
Immunotherapy via engineered therapeutic programs in tumors using RNA
使用 RNA 通过工程化治疗方案进行肿瘤免疫治疗
- 批准号:
10491263 - 财政年份:2021
- 资助金额:
$ 38.5万 - 项目类别:
Immunotherapy via engineered therapeutic programs in tumors using RNA
使用 RNA 通过工程化治疗方案进行肿瘤免疫治疗
- 批准号:
10330085 - 财政年份:2021
- 资助金额:
$ 38.5万 - 项目类别:
Immunotherapy via engineered therapeutic programs in tumors using RNA
使用 RNA 通过工程化治疗方案进行肿瘤免疫治疗
- 批准号:
10685607 - 财政年份:2021
- 资助金额:
$ 38.5万 - 项目类别:
Biodegradable nanoparticles, a genome editing platform to treat hemophilia
可生物降解的纳米颗粒,治疗血友病的基因组编辑平台
- 批准号:
9916793 - 财政年份:2017
- 资助金额:
$ 38.5万 - 项目类别:
Biodegradable nanoparticles, a genome editing platform to treat hemophilia
可生物降解的纳米颗粒,治疗血友病的基因组编辑平台
- 批准号:
9286161 - 财政年份:2017
- 资助金额:
$ 38.5万 - 项目类别:
Cell-specific and multifunctional drug formulations for in vivo delivery
用于体内递送的细胞特异性和多功能药物制剂
- 批准号:
9319782 - 财政年份:2016
- 资助金额:
$ 38.5万 - 项目类别:
相似国自然基金
髋关节撞击综合征过度运动及机械刺激动物模型建立与相关致病机制研究
- 批准号:82372496
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
探索在急性呼吸窘迫综合征动物模型和患者长时间俯卧位通气过程中动态滴定呼气末正压的意义
- 批准号:82270081
- 批准年份:2022
- 资助金额:76 万元
- 项目类别:面上项目
脆性X综合征动物模型中异常视觉信息处理和视觉注意力的神经环路机制研究
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
无菌动物模型与单细胞拉曼技术结合的猴与人自闭症靶标菌筛选及其机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
雌激素抑制髓系白血病动物模型中粒细胞异常增生的机制
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
Effects of tACS on alcohol-induced cognitive and neurochemical deficits
tACS 对酒精引起的认知和神经化学缺陷的影响
- 批准号:
10825849 - 财政年份:2024
- 资助金额:
$ 38.5万 - 项目类别:
Modeling, measurement and prediction of cardiac magneto-stimulation thresholds
心脏磁刺激阈值的建模、测量和预测
- 批准号:
10734438 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:
Unified, Scalable, and Reproducible Neurostatistical Software
统一、可扩展且可重复的神经统计软件
- 批准号:
10725500 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:
Prototype development and validation of soft robotic sensor arrays for mapping cardiac arrhythmia
用于绘制心律失常的软机器人传感器阵列的原型开发和验证
- 批准号:
10722857 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别: